Viral vector-based influenza vaccines. Issue 11 (1st November 2016)

• Record Type: Journal Article
• Authors: de Vries, Rory D.; Rimmelzwaan, Guus F.
• Is Part Of: Human vaccines & immunotherapeutics. Volume 12:Issue 11(2016)
• Page Start: 2881
• Page End: 2901
• Publication Date: 2016-11-01
• Subjects: adenovirus -- immunity -- influenza -- MVA -- vector -- vaccine; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2016.1210729
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Antigenic drift of seasonal influenza viruses and the occasional introduction of influenza viruses of novel subtypes into the human population complicate the timely production of effective vaccines that antigenically match the virus strains that cause epidemic or pandemic outbreaks. The development of game-changing vaccines that induce broadly protective immunity against a wide variety of influenza viruses is an unmet need, in which recombinant viral vectors may provide. Use of viral vectors allows the delivery of any influenza virus antigen, or derivative thereof, to the immune system, resulting in the optimal induction of virus-specific B- and T-cell responses against this antigen of choice. This systematic review discusses results obtained with vectored influenza virus vaccines and advantages and disadvantages of the currently available viral vectors.